Cas: 329-89-5 | Vimercati, Claudiopublished an article in 2014

6-Aminonicotinamide (cas:329-89-5)Name: 6-Aminonicotinamide is a well-established inhibitor of the NADP+-dependent enzyme, 6-phosphogluconate dehydrogenase (Ki = 0.46 μM). 6-Aminonicotinamide also reduces cardiovascular oxidative injury following ischemia/reperfusion.

Vimercati, Claudio;Qanud, Khaled;Mitacchione, Gianfranco;Sosnowska, Danuta;Ungvari, Zoltan;Sarnari, Roberto;Mania, Daniella;Patel, Neel;Hintze, Thomas H.;Gupte, Sachin A.;Stanley, William C.;Recchia, Fabio A. published 《Beneficial effects of acute inhibition of the oxidative pentose phosphate pathway in the failing heart》 in 2014. The article was appeared in 《American Journal of Physiology》. They have made some progress in their research.Name: 6-Aminonicotinamide The article mentions the following:

In vitro studies suggested that glucose metabolism through the oxidative pentose phosphate pathway (oxPPP) can paradoxically feed superoxide-generating enzymes in failing hearts. We therefore tested the hypothesis that acute inhibition of the oxPPP reduces oxidative stress and enhances function and metabolism of the failing heart, in vivo. In 10 chronically instrumented dogs, congestive heart failure (HF) was induced by high-frequency cardiac pacing. Myocardial glucose consumption was enhanced by raising arterial glycemia to levels mimicking postprandial peaks, before and after i.v. administration of the oxPPP inhibitor 6-aminonicotinamide (80 mg/kg). Myocardial energy substrate metabolism was measured with radiolabeled glucose and oleic acid, and cardiac 8-isoprostane output was used as an index of oxidative stress. A group of five chronically instrumented, normal dogs served as control. In HF, raising glycemic levels from ∼80 to ∼170 mg/dL increased cardiac isoprostane output by approx. twofold, whereas oxPPP inhibition normalized oxidative stress and enhanced cardiac oxygen consumption, glucose oxidation, and stroke work. In normal hearts glucose infusion did not induce significant changes in cardiac oxidative stress. Myocardial tissue concentration of 6P-gluconate, an intermediate metabolite of the oxPPP, was significantly reduced by ∼50% in treated vs. nontreated failing hearts, supporting the inhibitory effect of 6-aminonicotinamide. Our study indicates an important contribution of the oxPPP activity to cardiac oxidative stress in HF, which is particularly pronounced during common physiol. changes such as postprandial glycemic peaks. To complete the study, the researchers used 6-Aminonicotinamide (cas: 329-89-5) .

6-Aminonicotinamide (cas:329-89-5)Name: 6-Aminonicotinamide is a well-established inhibitor of the NADP+-dependent enzyme, 6-phosphogluconate dehydrogenase (Ki = 0.46 μM). 6-Aminonicotinamide also reduces cardiovascular oxidative injury following ischemia/reperfusion.

Reference:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics